Advaxis Research Accepted for American Association of Immunologists Annual Meeting, Demonstrates Reduction of Tumor Defenses

PRINCETON, N.J.--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that an abstract has been selected for poster & block symposium presentations at the American Association of Immunologists (AAI) Annual Meeting 2012 in Boston, MA, from May 4-8. The abstract is number 1334438, poster P150, entitled “Treatment with Lm-LLO immunotherapies lead to decreased Tregs and MDSC in the tumor microenvironment” by Dr. Reshma Singh, et al., Advaxis.

The abstract will show that in pre-clinical research (Lm)-LLO-based immunotherapies that secrete LLO-antigen fusion proteins reverse the immune suppression that exists within tumors to protect them from the immune system. Not only are the percentages of Regulatory T cells (Tregs) and Myeloid Derived Suppressor Cells (MDSC) in tumors reduced, but the immunosuppressive activity of these cells that persists is also reduced. Moreover, as this effect is not seen in the spleen or other non-cancerous (normal) peripheral tissues, it appears to be limited to the tumor microenvironment. These findings suggest that the side effects against normal tissues that are associated with immune-checkpoint blocking agents may not occur with Lm-LLO agents.

“The ability of Lm-LLO immunotherapies to reduce the effect of both major cell types associated with tumor protection while simultaneously stimulating strong innate and adaptive immune responses differentiates Advaxis’ Lm-LLO-based immunotherapies from other therapies,” commented Dr. John Rothman, Executive Vice President of Science and Operations at Advaxis. “The multiple, simultaneous, and integrated immune responses to living Lm-LLO agents enables a more comprehensive immune attack against cancer and other diseases than is possible with an antibody or small molecule.”

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website.

ADXS-HPV is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information
Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
dmoore@advaxis.com

Source: Advaxis, Inc.